SEC Form 4 · accession 0001193125-26-397955
Atrium Therapeutics, Inc. · RNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
W. Michael Flanagan
Director
Period of report
Sep 18, 2026
Accepted (ET)
Sep 22, 2026 · 4:20 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002093101
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 18, 2026 | F | 22,812 | $8.95 | D | 31,974 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.